<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164736">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01802697</url>
  </required_header>
  <id_info>
    <org_study_id>11-HMedIdeS-01</org_study_id>
    <secondary_id>2012-000969-21</secondary_id>
    <nct_id>NCT01802697</nct_id>
  </id_info>
  <brief_title>Safety Study on IdeS in Healthy Volounteers</brief_title>
  <official_title>A Phase i Single Center Study to Evalute the Safety, Tolerability and Pharmacokinetics of Intravenous IdeS After Administration of Single Ascending Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hansa Medical AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hansa Medical AB</source>
  <oversight_info>
    <authority>Sweden:  Swedish medicines product agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in man study to assess safety and tolerability of the IgG cleaving enzyme
      Immunoglobuli G degrading enzyme of streptococcus pyogenes (IdeS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>64 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of IdeS</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Total IgG concentration</measure>
    <time_frame>64 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IdeS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS Buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IdeS</intervention_name>
    <arm_group_label>IdeS</arm_group_label>
    <other_name>IdeS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PBS Buffer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and sign informed consent

          -  BMI 19-30

        Exclusion Criteria:

          -  Clinically significant disease

          -  Positive HIV, hepatistis B or C

               -  Drug abuse

          -  Smoking

          -  Use of medication except paracetamol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Malmqvist, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Unit, SUS, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena Winstedt, PhD</last_name>
    <phone>+46 46 16 56 75</phone>
    <email>lena.winstedt@hansamedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Unit, FoU centrum Skåne, Skåne University hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf Malmqvist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 28, 2013</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
